# OnCo record panku-esophagus01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/panku-esophagus01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "panku-esophagus01", "NCT06304974" ;
  schema:name "PANKU-Esophagus01 (BL-B01D1-305)"@en ;
  schema:description "The first bispecific ADC to extend both progression-free and overall survival in oesophageal cancer, for patients whose immunotherapy has stopped working."@en ;
  schema:url <https://onco.cc/trials/panku-esophagus01/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06304974>, <https://www.biospace.com/press-releases/izalontamab-brengitecan-iza-bren-demonstrates-statistically-significant-and-clinically-meaningful-improvements-in-overall-survival-and-progression-free-survival-in-patients-with-triple-negative-breast-cancer-and-esophageal-squamous-cell-carcinoma> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2024-03-19" ;
  onco:cancers <https://onco.cc/cancers/esophageal/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her3/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/> ;
  onco:trials <https://onco.cc/trials/bl-b01d1-307/> .